Theralase(R) Closes C$4.8 Million Offering
Toronto, Ontario--(Newsfile Corp. - May 20, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has closed its previously announced brokered private placement offering ("Brokered Offering
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-05-20 11:06 AM EDT | Theralase Technologies Inc.
Envoy Medical Announces New Patents Expanding Intellectual Property Portfolio in Fully Implanted Hearing Technology
White Bear Lake, Minnesota--(Newsfile Corp. - May 20, 2026) - Envoy Medical® Inc. (NASDAQ: COCH), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of multiple patents across Australia and Europe, as well as the upcoming grant of an additional European patent, further expanding the Company's intellectual property portfolio and reinforcing its position in the cochlear implant i
Biotechnologies, Soins de santé et hôpitaux
2026-05-20 8:30 AM EDT | Envoy Medical, Inc.
Sym Sciences Awarded $50,000 Grant to Advance IND-Ready Cannabinoid Research Platform
New York, New York--(Newsfile Corp. - May 20, 2026) - Sym Sciences announced today that it has been awarded a $50,000 grant from the to support the development of standardized, IND-ready cannabinoid materials for clinical research. The funding will enable Sym Sciences to expand its university research network and accelerate the preparation of regulatory-grade cannabinoid formulations designed for NIH-funded studies. The initiative is focused on streamlining the pathway from product deve
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-05-20 8:25 AM EDT | Sym Sciences
Resverlogix Closes US$2 Million Shares-for-Interest Private Placement
Calgary, Alberta--(Newsfile Corp. - May 19, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") announced today that it has closed a $2,760,057 (US$2,000,000) shares-for-interest private placement (the "Transaction") with an arm's length subscriber (the "Subscriber"). Under the terms of the Transaction, the Subscriber subscribed for 26,864,133 common shares at CAD$0.103 per share, equal to the applicable 5-day volume-weighted average price, for aggregate proceeds of CAD$2,760,057 (US
Technologies, Biotechnologies, Soins de santé et hôpitaux
2026-05-19 5:15 PM EDT | Resverlogix Corp.
Richards Group Inc. Announces May 2026 Dividend
Toronto, Ontario--(Newsfile Corp. - May 19, 2026) - Richards Group Inc. (TSX: RIC) (the "Company") announced today its cash dividend for the month ended May 31, 2026 of Cdn$0.11 per share. This dividend will be to shareholders of record at the close of business on May 29, 2026 and will be payable on June 12, 2026. Shareholders who are non-residents of Canada may be required to pay all withholding taxes payable in respect of any dividends of income by the Company, whether such dividends are
Soins de santé et hôpitaux, Produits ménagers / de consommation / cosmétiques, Pharmaceutique
2026-05-19 9:48 AM EDT | Richards Group Inc.
NorthPalm Capital Launches as AI-Augmented Investment Company
Toronto, Ontario--(Newsfile Corp. - May 19, 2026) - NorthPalm Capital Corp. (CSE: NP) ("NorthPalm" or the "Company") is pleased to announce the launch of NorthPalm Capital[1], an AI-augmented investment company focused on identifying and supporting high-growth opportunities across technology and digital asset sectors. The launch reflects NorthPalm's evolution into a leaner, high-conviction investment company with a modern approach to sourcing, evaluating, and act
Biotechnologies, Soins de santé et hôpitaux, Santé
2026-05-19 8:36 AM EDT | NorthPalm Capital Corp.
Conexeu Sciences Advances 3D Biofabricated Matrix to Move Breast Reconstruction Beyond Implants
Reno, Nevada--(Newsfile Corp. - May 19, 2026) -
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-05-19 8:30 AM EDT | Conexeu Sciences Inc.
WELL Health Announces Approval of Normal Course Issuer Bid
Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ("WELL" or the "Company"), a digital health company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that the Notice of Intention to Make a Normal Course Issuer Bid ("NCIB") it filed with the Toronto Stock Exchange ("TSX") has been appr
Technologies, Logiciels, Soins de santé et hôpitaux, Santé
2026-05-19 7:00 AM EDT | WELL Health Technologies Corp.
Cosmo Announces Completion of Phase II Enrolment in Distal Ulcerative Colitis Program
Dublin, Ireland--(Newsfile Corp. - May 18, 2026) - Cosmo N.V. (SIX: COPN) (XETRA: C43) (“Cosmo” or “the Company”) today announced the completion of patient enrolment in its Phase II clinical trial (EUCT number: 2023-506917-23-00) evaluating its novel investigational therapy, Rifamycin enema, for the treatment of distal ulcerative colitis (UC) and ulcerative proctitis. A total of 77 patients were enrolled at 24 clinical sites in Europe, reflecting strong
Soins de santé et hôpitaux, Santé
2026-05-18 1:03 AM EDT | Cosmo Pharmaceuticals N.V.
ADIA Nutrition, Inc. Reports Strong Revenue Growth and Operational Momentum for First Quarter 2026
Winter Park, Florida--(Newsfile Corp. - May 15, 2026) - ADIA Nutrition, Inc. (OTCQB: ADIA), a leader in advanced nutrition and regenerative health solutions, today announced its 3rd party reviewed financial results for the first quarter ended March 31, 2026, highlighting significant year-over-year revenue growth and continued expansion of its biologics and medical procedures segments.
Soins de santé et hôpitaux, Santé
2026-05-15 7:59 AM EDT | Adia Nutrition Inc.
AllStar Global Brands Announces Strategic Partnership with Riccione Femminile Calcio
Ontario and Riccione, Italy--(Newsfile Corp. - May 14, 2026) - AllStar Global Brands (OTCID: ALST) ("ASGB") is pleased to announce that an agreement has been reached to acquire a 60% ownership stake in Riccione Femminile Calcio for €50,000, marking the beginning of a long-term strategic partnership focused on developing women's football and international player pathways. As part of the agreement, ASGB will provide financial assistance, operational support, and access to d
Soins de santé et hôpitaux, Commerce de détail, Santé
2026-05-14 10:37 AM EDT | AllStar Health Brands, Inc.
Conexeu Sciences Unveils Defining Commitment: Architecting Bioregeneration(TM)
Reno, Nevada--(Newsfile Corp. - May 14, 2026) - Conexeu Sciences Inc. (the "Company" or "Conexeu") a medical device company advancing regenerative medicine through its patented bioregenerative extracellular matrix platform, today unveiled a new defining identity: Architecting Bioregeneration™.
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-05-14 8:30 AM EDT | Conexeu Sciences Inc.
Profound Medical Annual General and Special Meeting of Shareholders Voting Results
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - Profound Medical Corp. (TSX: PRN) (NASDAQ: PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders that was held today (the "Meeting"). A total of 25,347,133 common shares, representing 69.754% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in th
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-05-13 8:41 PM EDT | Profound Medical Corp.
TelyRx Announces First Quarter 2026 Financial Results
Clearwater, Florida--(Newsfile Corp. - May 12, 2026) - TelyRx Holdings Inc. (TSX: TELY) ("TelyRx" or the "Company"), a vertically integrated, technology-enabled healthcare and pharmacy services company, today announced financial results for the first quarter ended March 31, 2026. All dollar amounts are expressed in U.S. dollars. Highlights for the First Quarter of 2026 Revenue increased to $19.4 million, compared to $14.3 million in Q
Soins de santé et hôpitaux, Santé
2026-05-12 5:57 PM EDT | TelyRx
Kovo+ Holdings Inc. Appoints Matthew Woodin as Chief Financial Officer
Calgary, Alberta--(Newsfile Corp. - May 12, 2026) - Kovo+ Holdings Inc. (TSXV: KOVO) ("Kovo" or the "Company") today announced the appointment of Matthew Woodin as Chief Financial Officer, effective May 12, 2026, subject to approval from the TSXV. Woodin joins Kovo with more than 15 years of financial leadership experience in the healthcare sector, spanning provider organizations, payer systems, and multi-state operations. He has served in senior executive roles overseeing strategic fin
Technologies, Soins de santé et hôpitaux, Technologies de l’Internet
2026-05-12 5:30 PM EDT | Kovo+ Holdings Inc.
TelyRx to Host First Quarter 2026 Financial Results Conference Call on Wednesday, May 13, 2026 at 8:30 am ET
Clearwater, Florida--(Newsfile Corp. - May 12, 2026) - TelyRx Holdings Inc. (TSX: TELY) ("TelyRx" or the "Company"), a vertically integrated, technology-enabled healthcare and pharmacy services company, today announced it will host a conference call and webcast to discuss its first quarter 2026 financial results on Wednesday, May 13, 2026, at 8:30 a.m. Eastern Time (ET). The Company expects to report its first quarter 2026 financial results for the period ended March 31, 2026, after market cl
Soins de santé et hôpitaux, Santé
2026-05-12 10:45 AM EDT | TelyRx
Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - May 12, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing tec
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-05-12 7:00 AM EDT | Phio Pharmaceuticals Corp.
Resverlogix Announces One-Year Extension of Debenture
Calgary, Alberta--(Newsfile Corp. - May 11, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a one-year extension of the Company's US$6.0 million secured debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") (and payment of accrued interest thereon), extending the maturity date to May 13, 2027. In connection with the extension, the interest rate has been amended from 18% to 20% per annum, commencing on May 14, 2026. "
Technologies, Biotechnologies, Soins de santé et hôpitaux
2026-05-11 5:15 PM EDT | Resverlogix Corp.
FONAR Announces Financial Results for Fiscal 2026 Third Quarter and Nine-Month Period
Net Income decreased 25% to $2.3 million for the quarter ended March 31, 2026 as compared to the quarter ended March 31, 2025. Income from Operations for the quarter ended March 31, 2026 decreased 33% to $2.4 million as compared to the quarter ended March 31, 2025. Diluted Net Income Per Common Share Available to Common Stockholders decreased 35% to $0.24 per share for the quarter ended March 31, 2026 as compared to
Technologies, Soins de santé et hôpitaux
2026-05-11 4:15 PM EDT | Fonar Corporation
ADIA Nutrition Announces IRB Approval of All Four Clinical Studies and Registration of Kidney Health Study on ClinicalTrials.gov
Winter Park, Florida--(Newsfile Corp. - May 11, 2026) - ADIA Nutrition, Inc. (OTCQB: ADIA), a publicly traded company advancing regenerative medicine through its subsidiary Adia Med of Winter Park, LLC, today announced that all four of its planned clinical studies have received Institutional Review Board (IRB) approval. This milestone enables the continued execution and launch of human trials evaluating the safety and potential efficacy of the Company's proprietary AdiaVita™ stem cell a
Soins de santé et hôpitaux, Santé
2026-05-11 10:04 AM EDT | Adia Nutrition Inc.